HighTower Advisors
WX

HighTower Advisors’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

HighTower Advisors’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-57,465
Closed -$2.48M – 2200
2015
Q3 		$2.48M Sell
57,465
-14,557
-20% -$614K 0.03% 542
2015
Q2 		$3.04M Buy
+72,022
New +$3.04M 0.05% 420
2015
Q1 		– Sell
-57,883
Closed -$1.95M – 1752
2014
Q4 		$1.95M Buy
57,883
+6,793
+13% +$240K 0.03% 588
2014
Q3 		$1.79M Buy
51,090
+6,449
+14% +$221K 0.03% 592
2014
Q2 		$1.47M Buy
44,641
+11,184
+33% +$383K 0.03% 666
2014
Q1 		$1.23M Buy
33,457
+4,535
+16% +$166K 0.02% 669
2013
Q4 		$1.11M Buy
28,922
+11,052
+62% +$349K 0.02% 663
2013
Q3 		$490K Buy
+17,870
New +$423K 0.01% 849

Other funds holding WX

Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
CCS
Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

HighTower Advisors's WX Position: Q4 2015 in Review

HighTower Advisors sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2015, closing a stake of 57,465 shares — an estimated $2.48M sold.

HighTower Advisors first reported a position in WX in Q3 2013 and held it in 8 quarters. The position peaked at $3.04M in Q2 2015. 2 funds tracked by Wall St. Rank hold WX as of Q4 2015.

  • HighTower Advisors reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2015 after selling out during the quarter.
  • HighTower Advisors sold 57,465 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2015, an estimated $2.48M.
  • HighTower Advisors first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q3 2013 and held it in 8 quarters.
  • HighTower Advisors's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $3.04M in Q2 2015.
  • 2 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2015.

Based on HighTower Advisors's 13F filing for Q4 2015, filed 12 Feb 2016.